

## Prestige BioPharma Participates in Korea-EU Global Vaccine Partnership Business Forum in Brussels



[The South Korean Trade Minister Yeo Han-Koo (left), Vice Chairman of PBP Group Michael Jinwoo Kim (right)]

**[12 October 2021]** / Prestige BioPharma Limited (PBP), a Singapore-based biopharmaceutical with global presence, announced that PBP took part in a Korea-EU Global Vaccine Partnership Business Forum in Brussels, on October 08, 2021. Those attending included the South Korean Minister of Health and Welfare Kwon Deok-cheol, the South Korean Trade Minister Yeo Han-Koo, officials of the EU commission, Coalition for Epidemic Preparedness Innovations (CEPI), EU's Bio Supply Management Alliance (BSMA) and the representatives of Korea-EU vaccine companies.

At the partnership forum, Vice Chairman of PBP Group Michael Jinwoo Kim gave a presentation on PBP's business plan and vaccine production capacity to the Korea-EU government officials, and PBP discussed cooperation with the EU pharmaceuticals who have proprietary self-amplifying mRNA vaccine technology and cancer vaccine platform. There is potential to generate synergy between PBP vaccine business and these EU vaccine companies as PBP ultimately aims to develop its own vaccine products.

EU's biomanufacturing equipment suppliers also attended the forum and showed interest in Korea's vision for hosting an Asian vaccine production hub. PBP had a discussion with the manufacturing equipment supplier specialising in Drug Product (DP) bioprocessing equipment to secure a reliable supply chain for its vaccine business.

PBP's CEO, Dr Lisa S. Park commented, "we incorporated Innovative Discovery Center (IDC) in Busan, Korea this year and its global-scale R&D center will be completed next year" and "PBP will ultimately develop our own vaccine products and novel antibody therapeutics in the IDC Busan through innovative cooperation with global vaccine companies and organisations".